{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:27:14Z","timestamp":1777400834556,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.remnie.2025.500082","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:14:38Z","timestamp":1736381678000},"page":"500082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["State of the art and future perspectives of new radionuclides in Nuclear Medicine"],"prefix":"10.1016","volume":"44","author":[{"given":"J.J.","family":"Rosales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Arcocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roteta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4469-0528","authenticated-orcid":false,"given":"R.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Quincoces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500082_bib0005","series-title":"Terapia Radiometab\u00f3lica \u201cTeragnosis\u201d","author":"Alonso","year":"2023"},{"key":"10.1016\/j.remnie.2025.500082_bib0010","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/MNM.0000000000001422","article-title":"Production of copper-64 using a hospital cyclotron: targetry, purification and quality analysis","volume":"42","author":"Jauregui-Osoro","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.remnie.2025.500082_bib0015","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.3390\/ijms24119154","article-title":"Recent advances in 64Cu\/67Cu-based radiopharmaceuticals","volume":"24","author":"Krasnovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","article-title":"Choice is good at times: the emergence of [64Cu]Cu-DOTATATE\u2013based somatostatin receptor imaging in the era of [68Ga]Ga-DOTATATE","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0025","series-title":"Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications","year":"2022"},{"key":"10.1016\/j.remnie.2025.500082_bib0030","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","article-title":"Marshalling the potential of auger electron radiopharmaceutical therapy","volume":"64","author":"Bolcaen","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0035","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/molecules27051501","article-title":"67Cu production capabilities: a mini review","volume":"27","author":"Mou","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.remnie.2025.500082_bib0040","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abca52","article-title":"Imaging and dosimetric characteristics of 67 Cu","volume":"66","author":"Merrick","year":"2021","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.remnie.2025.500082_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-022-00738-6","article-title":"Recent advances in cancer imaging with 64CuCl2 PET\/CT","volume":"56","author":"Peng","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500082_bib0050","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1158\/0008-5472.CAN-12-0888","article-title":"Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy","volume":"72","author":"Kuo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.remnie.2025.500082_bib0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.117.195628","article-title":"64 CuCl 2 PET\/CT in prostate cancer relapse","volume":"59","author":"Piccardo","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/RLU.0000000000003658","article-title":"Efficacy and safety of the 64Cu(II)Cl2 PET\/CT for urological malignancies","volume":"46","author":"Mascia","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11307-022-01769-3","article-title":"Diagnostic and dosimetry features of [64Cu]CuCl2 in high-grade paediatric infiltrative gliomas","volume":"25","author":"Fiz","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.remnie.2025.500082_bib0070","first-page":"143","article-title":"Evaluation of non-small cell lung cancer by PET\/CT with 64CuCl2: initial experience in humans","volume":"10","author":"Garc\u00eda-P\u00e9rez","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500082_bib0075","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2017.12.022","article-title":"Visualization of the therapeutic efficacy of a gene correction approach in Wilson\u2019s disease by laser-ablation inductively coupled mass spectrometry","volume":"68","author":"Moreno","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.remnie.2025.500082_bib0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.30535","article-title":"Liver expression of a MiniATP7B gene results in long\u2010term restoration of copper homeostasis in a Wilson disease model in mice","volume":"70","author":"Murillo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.remnie.2025.500082_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2022.06.001","article-title":"High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson\u2019s disease","volume":"26","author":"Murillo","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.remnie.2025.500082_bib0090","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2967\/jnumed.119.240143","article-title":"64 Cu-DOTATATE PET\/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms","volume":"61","author":"Carlsen","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.remnie.2025.500082_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/1061186X.2016.1154564","article-title":"Small-molecule PSMA ligands. Current state, SAR and perspectives","volume":"24","author":"Machulkin","year":"2016","journal-title":"J Drug Target"},{"key":"10.1016\/j.remnie.2025.500082_bib0110","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/RLU.0000000000003758","article-title":"A comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 patients with metastatic prostate cancer","volume":"47","author":"Cardoza-Ochoa","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0115","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1021\/acs.molpharmaceut.8b00371","article-title":"Preclinical study of a fully human anti-PD-L1 antibody as a theranostic agent for cancer immunotherapy","volume":"15","author":"Xu","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0120","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/acsabm.0c01555","article-title":"Successful application of CuAAC click reaction in constructing 64 Cu-labeled antibody conjugates for immuno-PET imaging","volume":"4","author":"Lee","year":"2021","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.remnie.2025.500082_bib0125","doi-asserted-by":"crossref","first-page":"28316","DOI":"10.1073\/pnas.2009960117","article-title":"Harnessing 64 Cu\/ 67 Cu for a theranostic approach to pretargeted radioimmunotherapy","volume":"117","author":"Kein\u00e4nen","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.remnie.2025.500082_bib0130","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.2174\/0929867327999200727190423","article-title":"203\/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer","volume":"27","author":"Li","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.remnie.2025.500082_bib0135","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1039\/D1DT01653A","article-title":"Getting a lead on Pb 2+ -amide chelators for 203\/212 Pb radiopharmaceuticals","volume":"50","author":"Ingham","year":"2021","journal-title":"Dalton Trans"},{"key":"10.1016\/j.remnie.2025.500082_bib0140","first-page":"166","article-title":"Bifunctional chelates for metal nuclides","volume":"52","author":"Brechbiel","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500082_bib0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0969-8051(99)00086-4","article-title":"Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb","volume":"27","author":"Chappell","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.remnie.2025.500082_bib0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2967\/jnumed.119.229393","article-title":"Preclinical evaluation of 203\/212 Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer","volume":"61","author":"Banerjee","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jlcr.3825","article-title":"Preparation of the alpha\u2010emitting prostate\u2010specific membrane antigen targeted radioligand [212 Pb]Pb\u2010NG001 for prostate cancer","volume":"63","author":"Stenberg","year":"2020","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0160","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?","volume":"46","author":"Dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500082_bib0165","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.3390\/ijms22094815","article-title":"Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer","volume":"22","author":"Stenberg","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0170","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.humpath.2006.04.004","article-title":"HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer","volume":"37","author":"Montironi","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.remnie.2025.500082_bib0175","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2012.1357","article-title":"Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice","author":"Dong","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.remnie.2025.500082_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb","volume":"8","author":"Boudousq","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.remnie.2025.500082_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.04.005","article-title":"Preparation of 212 Pb-labeled monoclonal antibody using a novel 224 Ra-based generator solution","volume":"51","author":"Westr\u00f8m","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.remnie.2025.500082_bib0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3934\/medsci.2015.3.228","article-title":"Application of 212Pb for targeted \u03b1-particle therapy (TAT): pre-clinical and mechanistic understanding through to clinical translation","volume":"2","author":"Yong","year":"2015","journal-title":"AIMS Med Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0195","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2967\/jnumed.107.048553","article-title":"203 Pb-labeled \u03b1-melanocyte\u2013stimulating hormone peptide as an imaging probe for melanoma detection","volume":"49","author":"Miao","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau4445","article-title":"68 Ga-DOTA-GGNle-CycMSH hex targets the melanocortin-1 receptor for melanoma imaging","volume":"10","author":"Yang","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9610","article-title":"A phase I\/IIa of [212 Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma","volume":"42","author":"Morris","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remnie.2025.500082_bib0210","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1535-7163.MCT-18-1103","article-title":"Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model","volume":"18","author":"Stallons","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.remnie.2025.500082_bib0215","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1 -emitter therapy with 212 Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0220","first-page":"321","article-title":"Targeting the BB2 receptor in prostate cancer using a Pb-203 labeled peptide","volume":"58","author":"Okoye","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"Kasten","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.remnie.2025.500082_bib0230","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.3390\/ijms25115954","article-title":"Towards clinical development of scandium radioisotope complexes for use in nuclear medicine: encouraging prospects with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and its analogues","volume":"25","author":"Ioannidis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2021.109599","article-title":"Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems","volume":"170","author":"Rosar","year":"2021","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.remnie.2025.500082_bib0240","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/diagnostics11101826","article-title":"Fifty shades of scandium: comparative study of PET capabilities using Sc-43 and Sc-44 with respect to conventional clinical radionuclides","volume":"11","author":"Lima","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.remnie.2025.500082_bib0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874471016666221111154424","article-title":"Current state of 44Ti\/44Sc radionuclide generator systems and separation chemistry","volume":"16","author":"Schmidt","year":"2023","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0250","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.apradiso.2019.05.020","article-title":"Comparison of separation methods for 47Ca\/47Sc radionuclide generator","volume":"151","author":"Pawlak","year":"2019","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.remnie.2025.500082_bib0255","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.3390\/ijms24087400","article-title":"Scandium-44: diagnostic feasibility in tumor-related angiogenesis","volume":"24","author":"Trencs\u00e9nyi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0260","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ccr.2009.03.013","article-title":"The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N\u2032,N\u2033,N\u2032\u2033-tetraacetic acid (H4DOTA): structural overview and analyses on structure\u2013stability relationships","volume":"253","author":"Viola-Villegas","year":"2009","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.remnie.2025.500082_bib0265","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jinorgbio.2010.11.003","article-title":"Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals","volume":"105","author":"Majkowska-Pilip","year":"2011","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.remnie.2025.500082_bib0270","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.apradiso.2012.03.005","article-title":"Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc","volume":"70","author":"Pruszy\u0144ski","year":"2012","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.remnie.2025.500082_bib0275","first-page":"124","article-title":"First-in-human PET\/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44 Sc-DOTATOC: a proof-of-concept study","volume":"32","author":"Singh","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0280","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin\u2013RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0285","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1021\/mp500343j","article-title":"44 Sc: an attractive isotope for peptide-based PET imaging","volume":"11","author":"Hernandez","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-016-0013-5","article-title":"44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations","volume":"1","author":"Domnanich","year":"2017","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.remnie.2025.500082_bib0295","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.115.170977","article-title":"Bombesin-targeted PET of prostate cancer","volume":"57","author":"Mansi","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500082_bib0300","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.apradiso.2012.08.004","article-title":"44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?","volume":"70","author":"Koumarianou","year":"2012","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.remnie.2025.500082_bib0305","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.7150\/thno.20586","article-title":"Clinical translation and first in-human use of [44 Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer","volume":"7","author":"Eppard","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.remnie.2025.500082_bib0310","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1021\/acs.bioconjchem.0c00574","article-title":"Homologous structural, chemical, and biological behavior of Sc and Lu complexes of the Picaga bifunctional chelator: toward development of matched theranostic pairs for radiopharmaceutical applications","volume":"32","author":"Vaughn","year":"2021","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.remnie.2025.500082_bib0315","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9SC04655K","article-title":"Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44","volume":"11","author":"Vaughn","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.remnie.2025.500082_bib0320","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1021\/acs.molpharmaceut.1c00711","article-title":"Evaluation of 177 Lu and 47 Sc Picaga-linked, prostate-specific membrane antigen-targeting constructs for their radiotherapeutic efficacy and dosimetry","volume":"18","author":"Vaughn","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.remnie.2025.500082_bib0325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40336-017-0231-1","article-title":"Molecular mechanisms of hypoxia in cancer","volume":"5","author":"Challapalli","year":"2017","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.remnie.2025.500082_bib0330","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/ph15060666","article-title":"Synthesis, physicochemical, labeling and in vivo characterization of 44Sc-labeled DO3AM-NI as a hypoxia-sensitive PET probe","volume":"15","author":"Sz\u00fccs","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.remnie.2025.500082_bib0335","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/CM9.0000000000001200","article-title":"Targeting neuropilin-1 interactions is a promising anti-tumor strategy","volume":"134","author":"Liu","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.remnie.2025.500082_bib0340","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/biomedicines11020564","article-title":"Scandium-44 radiolabeled peptide and peptidomimetic conjugates targeting neuropilin-1 co-receptor as potential tools for cancer diagnosis and anti-angiogenic therapy","volume":"11","author":"Mas\u0142owska","year":"2023","journal-title":"Biomedicines"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:53:20Z","timestamp":1740725600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2253808925000011"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500082","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art and future perspectives of new radionuclides in Nuclear Medicine","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2024.500082","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500082"}}